Stevanato Group Expands Pen Injector Platform

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D pen injector technology.

The extension gives the company exclusivity to offer the technology to support a broader range of drugs for its biopharma customers beyond diabetes, including therapeutic areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorders, arthritis, and others. Stevanato Group is focused on delivering an integrated end-to-end product portfolio, supported by its scientific and analytical processes and services.

Utilizing the Axis-D pen injector technology, Stevanato Group has developed its Alina variable-dose and fixed-dose pen injector platform compatible with established therapeutic regimens as well as innovative drug therapies related to diabetes care.

“The expansion of this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market,” said Franco Moro, CEO, Stevanato Group. “We are constantly working with our customers to satisfy their needs, as we continue to experience an increase in demand for our high-value solutions and a shift up of the product value chain.”

Adam Stops, head of product management for drug delivery systems, Stevanato Group, said, "The Alinad pen injector platform combines ease of use for patients with faster time-to-market access for pharma organizations. Our patient-centric solutions aim to improve the lives of patients as they manage their complex health conditions. The extension of our licensing agreement with Haselmeier enables us to offer this innovative technology for use in additional therapeutic areas—helping even more patients—as we continue the expansion of our integrated capabilities in the proprietary drug delivery space.”